Complex prolactin crosstalk in breast cancer: New therapeutic implications

被引:42
作者
Carver, Kristopher C. [1 ,2 ,3 ]
Arendt, Lisa M. [1 ,2 ]
Schuler, Linda A. [1 ,2 ,3 ]
机构
[1] Univ Wisconsin, Dept Comparat Biosci, Madison, WI 53706 USA
[2] Univ Wisconsin, Cellular & Mol Biol Program, Madison, WI 53706 USA
[3] Univ Wisconsin, Biotechnol Training Program, Madison, WI 53706 USA
关键词
Prolactin; Breast cancer; Signaling crosstalk; Targeted therapeutics; ESTROGEN-RECEPTOR-ALPHA; ACTIVATED PROTEIN-KINASE; EPIDERMAL-GROWTH-FACTOR; MAMMARY-GLAND DEVELOPMENT; STAT 5A EXPRESSION; PROGESTERONE-RECEPTOR; ACQUIRED-RESISTANCE; MOUSE MAMMARY; SIGNAL TRANSDUCER; EPITHELIAL-CELLS;
D O I
10.1016/j.mce.2009.03.014
中图分类号
Q2 [细胞生物学];
学科分类号
071009 ; 090102 ;
摘要
The contributions of prolactin (PRL) to breast cancer are becoming increasingly recognized. To better understand the role for PRL in this disease, its interactions with other oncogenic growth factors and hormones must be characterized. Here, we review our current understanding of PRL crosstalk with other mammary oncogenic factors, including estrogen, epidermal growth factor (EGF) family members, and insulin-like growth factor-I (IGF-I). The ability of PRL to potentiate the actions of these targets of highly successful endocrine and molecular therapies suggests that PRL and/or its receptor (PRLR) may be an attractive therapeutic target(s). We discuss the potential benefit of PRL/PRLR-targeted therapy in combination with established therapies and implications for de novo and acquired resistance to treatment. (C) 2009 Elsevier Ireland Ltd. All rights reserved.
引用
收藏
页码:1 / 7
页数:7
相关论文
共 117 条
[1]   Transgenic models to study actions of prolactin in mammary neoplasia [J].
Arendt, Lisa M. ;
Schuler, Linda A. .
JOURNAL OF MAMMARY GLAND BIOLOGY AND NEOPLASIA, 2008, 13 (01) :29-40
[2]   Prolactin drives estrogen receptor-α-dependent ductal expansion and synergizes with transforming growth factor-α to induce mammary tumors in males [J].
Arendt, Lisa M. ;
Schuler, Linda A. .
AMERICAN JOURNAL OF PATHOLOGY, 2008, 172 (01) :194-202
[3]   Prolactin-Growth Factor Crosstalk Reduces Mammary Estrogen Responsiveness Despite Elevated ERα Expression [J].
Arendt, Lisa M. ;
Grafwallner-Huseth, Tara L. ;
Schuler, Linda A. .
AMERICAN JOURNAL OF PATHOLOGY, 2009, 174 (03) :1065-1074
[4]   Prolactin potentiates transforming growth factor α induction of mammary neoplasia in transgenic mice [J].
Arendt, LM ;
Rose-Hellekant, TA ;
Sandgren, EP ;
Schuler, LA .
AMERICAN JOURNAL OF PATHOLOGY, 2006, 168 (04) :1365-1374
[5]   Clinical efficacy of the aromatase inhibitor anastrozole in relation to prolactin secretion in heavily pretreated metastatic breast cancer [J].
Barni, S ;
Lissoni, P ;
Meregalli, S ;
Ardizzoia, A ;
Mengo, S ;
Musco, F ;
Merlini, D ;
Tancini, G .
TUMORI, 1998, 84 (01) :45-47
[6]   What can we learn from rodents about prolactin in humans? [J].
Ben-Jonathan, Nira ;
LaPensee, Christopher R. ;
LaPensee, Elizabeth W. .
ENDOCRINE REVIEWS, 2008, 29 (01) :1-41
[7]   Activated ERK1/2 and phosphorylated oestrogen receptor α are associated with improved breast cancer survival in women treated with tamoxifen [J].
Bergqvist, Jenny ;
Elmberger, Goran ;
Ohd, John ;
Linderholm, Barbro ;
Bjohle, Judith ;
Hellborg, Henrik ;
Nordgren, Hans ;
Borg, Anna-Lena ;
Skoog, Lambert ;
Bergh, Jonas .
EUROPEAN JOURNAL OF CANCER, 2006, 42 (08) :1104-1112
[8]  
Bhatavdekar J M, 1994, Eur J Surg Oncol, V20, P118
[9]   Intrinsic and acquired resistance to EGFR inhibitors in human cancer therapy [J].
Bianco, R ;
Troiani, T ;
Tortora, G ;
Ciardiello, F .
ENDOCRINE-RELATED CANCER, 2005, 12 :S159-S171
[10]   Cross-talk between Stat5b and estrogen receptor-α and -β in mammary epithelial cells [J].
Björnström, L ;
Kilic, E ;
Norman, M ;
Parker, MG ;
Sjöberg, M .
JOURNAL OF MOLECULAR ENDOCRINOLOGY, 2001, 27 (01) :93-106